Home›Screener›PASG›Profile
D
35/100

Passage Bio

PASGGene Therapy
← Signals View
📋
Analyst Summary
✓ VERIFIED2026-04-11

Passage Bio (PASG) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov[3], including 1 Phase 2[1], 1 Phase 1[2].

PASG has 2 Form 4 insider filings recorded at the SEC in the past 30 days[4].

Sources

  1. ClinicalTrials.gov (2026-04-11) ↗
  2. ClinicalTrials.gov (2026-04-11) ↗
  3. ClinicalTrials.gov (2026-04-11) ↗
  4. SEC EDGAR · 0001787297 (2026-04-11) ↗
🔬
Clinical Trials
1
NCT04747431Frontotemporal Dementia, FTD, FTD-GRN, Dementia Frontotemporal, C9orf72
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
👤
Insider Activity
1
2 filings
Source ↗
sec_edgar · Retrieved 2026-04-11
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-132026-06-02
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials1
Sector Peers (Gene Therapy)
BLUEbluebird bio
C
VRTXVertex Pharmaceuticals
C
RCKTRocket Pharmaceuticals
C
SRPTSarepta Therapeutics
D
GBIOGeneration Bio
D
Data Provenance
cik1 verified
clinical trial1 verified
insider buy1 verified
trial count3 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR